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SYNERGY OF BCL2 AND HISTONE DEACETYLASE INHIBITION AGAINST
LEUKEMIC CELLS FROM CUTANEOUS T-CELL LYMPHOMA PATIENTS.
Benoit Cyrenne, Julia Lewis, Jason Weed, Kacie Carlson, Fatima Mirza,
Francine Foss, and Michael Girardi. Department of Dermatology, Yale University,
School of Medicine, New Haven, CT.
The presence and degree of peripheral blood involvement in patients with
cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome. Available
systemic therapies for CTCL may variably decrease tumor burden and improve
quality of life, but offer limited effects on survival; thus, novel approaches to the
treatment of advanced stages of this non-Hodgkin lymphoma are clearly
warranted. Mutational analyses of CTCL patient peripheral blood malignant cell
samples suggested the anti-apoptotic mediator BCL2 as a potential therapeutic
target. To test this, we developed a screening assay for evaluating the sensitivity
of CTCL cells to targeted molecular agents, and compared a novel BCL2
inhibitor, venetoclax, alone and in combination with a histone deacetylase
(HDAC) inhibitor, vorinostat or romidepsin. Peripheral blood CTCL malignant
cells were isolated from 25 patients and exposed ex vivo to the three drugs alone
and in combination, and comparisons were made to four CTCL cell lines (Hut78,
Sez4, HH, MyLa). The majority of CTCL patient samples were sensitive to
venetoclax, and BCL2 expression levels were negatively correlated (r=-0.52,
P=.018) to IC50 values. Furthermore, this anti-BCL2 effect was markedly
potentiated by concurrent HDAC inhibition with 93% of samples treated with
venetoclax and vorinostat and 73% of samples treated with venetoclax and
romidepsin showing synergistic effects. These data strongly suggest that
concurrent BCL2 and HDAC inhibition may offer synergy in the treatment of
patients with advanced CTCL. By using combination therapies and correlating
response to gene expression in this way, we hope to achieve more effective and
personalized treatments for CTCL.
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Introduction

Diagnosis, Prognosis, and Current Therapies
Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin
lymphoma of the skin-homing CD4+ memory T-cells. CTCL is a group of
malignancies with a variety of clinical manifestations, the majority of which may
be categorized along the mycosis fungoides (MF) and Sézary syndrome
spectrum. The overall annual incidence of CTCL in the United States is 6.4 cases
per million persons, as calculated using Surveillance, Epidemiology, and End
Results (SEER) registry data.1 CTCL makes up 71% of all primary cutaneous
lymphoma cases and the remaining 29% are predominantly B-cell derived
neoplasms.2,3 In its early stages, mycosis fungoides (MF) is typically an indolent
disease characterized by localized skin patches, plaques and tumors, comprising
of 50% of all CTCL cases. In contrast, Sézary syndrome (SS) is a more
aggressive form of CTCL presenting with erythroderma, and frequently,
involvement of the lymph nodes, spleen, and liver. As the disease progresses,
new lesions may spread, and existing lesions may enlarge in both size and
thickness. In advanced disease, such as leukemic CTCL, malignant T-cells may
predominate the peripheral lymphocyte compartment, or invade the viscera.4 In
cases of advanced disease the loss of the normal T-cell receptor (TCR) diversity
leads to significant immunosuppression, leading to a high incidence of
opportunistic infections, and mortality.5
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Diagnosing CTCL has been a consistent struggle for physicians and
patients since it was first described in 1806. While classically MF presents as
well demarcated patches involving sun-protected skin in a “bathing-suit”
distribution, there is significant overlap in clinical features with benign
dermatoses, such as eczema or psoriasis.4,6 Additionally, there may be
alterations in pigmentation—either hypo- or hyper-pigmentation—and changes in
hair growth patterns, such as alopecia.4,6 Initial diagnosis thus relies on biopsy.
Histologically, MF is characterized by epidermotropism with Pautrier’s
microabscesses; but much like the clinical picture, the findings on biopsy show
high degree of variability, and may resemble benign inflammatory disorders such
as pityriasis lichenoides, granuloma annulare, gyrate erthema, or lichen planus.
This ambiguity in biopsy results frequently leads to the need for multiple biopsies
and a delayed diagnosis, taking an average of 6 years from the initial
presentation.7
This uncertainty in both clinical and histopathological diagnoses has led to
the development of more sensitive and specific tests. CTCL features a T-cell
clone which may be detected via polymerase chain reactions (PCR) of the T-cell
receptor within the skin (i.e. fresh, frozen, or formalin-fixed paraffin-embedded
biopsy specimens), the peripheral blood, or lymph node. This test, however, has
limited utility due to the low concentration of malignant cells, leading to falsenegatives and the frequent presence of oligoclonal expansion in other
inflammatory disorders, resulting in false positives.7–10 Despite these limitations,
the identification of the same clone from two biopsy sites provides a more
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specific diagnostic test for MF.7,11 Newer techniques to assess T-cell clonality
such as high throughput sequencing show improved sensitivity for detection of
malignancy.6,7,12 The rapid identification of CTCL upon presentation is essential
to improving clinical outcomes, as increased length of time to diagnosis
correlates with decreased survival.13
The identification of the prototypical Sézary cells, with their distinct
cerebriform nuclei, was initially the essential diagnostic test for blood
involvement, and remains within the 2007 update of the International Society for
Cutaneous Lymphomas (ISCL) and the European Organization for Research and
Treatment of Cancer (EORTC) guidelines for diagnosis and staging of CTCL.14
The ability to identify the cell surfaces markers of circulating T-cells, specifically
with the phenotype CD4+ CD7- and/or CD26-, on peripheral blood flow cytometry
has improved identification of peripheral malignant T-cell populations. Flow
cytometry has also proved useful in the identification of clonality via the
quantification of TCR β chain variable region (TCR-Vβ) family usage.15,16 The
practical application of TCR-Vβ analysis is hindered by the high degree of
variability among expression TCRs, and the limited number of Vβ antibodies
present in commercial assays, though the absence of Vβ reactivity to a given
assay can also be used as an indirect marker of clonality.17 Gibson et al. propose
new criteria for staging of blood involvement that includes tests for clonality such
as the aforementioned TCR-PCR and TCR-Vβ flow cytometry analysis.18
The rapid and accurate diagnosis of CTCL in the skin and blood is critical
for proper treatment. While patients with skin-limited patch disease, classified as
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stage IA, have similar life expectancies as the general population a 5-year
survival rate of 94-100%, blood and lymph node involvement are independent
predictors of poor survival outcomes.19–21 In advanced stages, CTCL is a fatal
disease that is incurable with conventional therapies, with a 0-18% 5- year
survival rate among stage IV-B patients.20,22 Additional factors associated with
worse prognosis include elevated lactate dehydrogenase, increased age, large
cell transformation, degree of peripheral blood involvement, and the
folliculotropic-MF variant.
While other lymphoproliferative diseases, such as ALL or CLL, may be risk
stratified by cytogenetic findings, no similar criteria exists in CTCL. Extensive
work has been performed to identify patterns in genetic alterations and
expression that correlate to worse survival. Cluster analysis of genetic
expression from skin biopsies of CTCL patients led to the identification of three
patient clusters consisting of earliest stage disease (stages I-A and I-B), more
extensive disease (stages I-B and III), and tumor type disease (stage IIB), of
which the two latter clusters were associated with worse treatment response and
survival.23,24
Treatment strategies for CTCL are as heterogeneous as the disease itself.
The site of disease and the degree of involvement, as well as patient and
physician preference will largely dictate the specific prescribed course. For skinlimited disease such as MF, skin-directed treatments are preferred, such as high
potency topical corticosteroids, phototherapy, nitrogen mustard-based therapies
and radiation therapy. In the case of more advanced disease such as extensive
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plaque, tumor, and/or leukemic CTCL, systemic therapies are indicated. These
include extracorporeal photopheresis, interferon-base therapies, bexarotene, and
methotrexate. With rare exceptions in cases of hematopoietic cell
transplantation,25 the overall response rates for novel agents including retinoids,
HDAC inhibitors, and pralatrexate range from 30-50% and are generally not
durable.26 There remains an unmet medical need for new and more effective
treatments, which the work of this thesis aims to address.

Genetic Alterations in CTCL
Recent studies5,27–30 have made significant strides in our understanding of
the molecular pathogenesis of CTCL, most notably via exome sequencing and
expression analysis. These analyses have shown a predominance of gene copy
number alterations (GCNA) over single nucleotide variant (SNV) mutations,
without evidence of common chromosomal translocations. The preponderance of
GCNAs among CTCL patients indicates a significant degree of chromosomal
instability. Although Döbbeling et al. found both CTCL patient samples and cells
lines to lack expression of recombination-activating genes (RAG), the high
frequency of focal deletions observed suggest possible involvement of RAG
proteins which cause breakpoints in DNA via endonuclease-mediated cleavage,
and are necessary for V(D)J (V, variability; D, diversity; J, joining)
recombination.5,31 RAG cleavage sites can be identified by the presence of RAG
heptamers, which were found adjacent to greater than 12% of CTCL deletions.5
Others have suggested that ectopic expression of germ cell proteins in CTCL
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leads to disordered mitosis, and high rates of double-stranded DNA breaks.
Several germ cell proteins were found to be highly expressed in CTCL cells
relative to healthy memory T-cells, and may be responsible for or associated with
severe chromosomal instability– in particular, cancer testis genes responsible for
the initiation of meiosis, strand breaks and subsequent homologous
recombination and the formation of synaptonemal complexes.32,33
Other mutations in genes involved in DNA repair and genome
maintenance–such as POT1, ATM, and BRAC2–have also been identified as
occurring in SS patients, and may also contribute to the high degree of genetic
variability in CTCL.34 ATM and POT1 are involved in telomere maintenance and
their derangement may lead to the telomere shortening observed in CTCL.
Catastrophic telomere shortening may also lead to chromothripsis, and nearglobal chromosomal changes, such as those observed in CTCL patient cells. 35,36
SNV mutations, which comprise of <10% of all driver mutations in CTCL,
are also of interest in the pathogenesis of CTCL. The number of patients
examined via exome sequencing and expression analysis limits power in genetic
studies, which require cohorts including a minimum of 200 samples for accurate
and complete identification.37 Despite these limitations, point mutations have
been put forth as likely driver mutations, including within CD28. Alternatively,
genetic shuffling may result in a fusion product, for example, the CD28-CTLA4
protein that can cause constitutive activation of T-cells.38 Other common
mutations observed in CTCL patient cohorts include RHOA, BRAF, STAT5B,
PLCG1 and NFKB2.5 A new analysis of published CTCL sequencing data
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suggests that the number of SNV driver mutations is greater than previously
reported. Among these are 5 genes not previously associated with another
malignancy: ARHGEF3, CSNK1A1, RLTPR, PTPRN2, and RARA.37
The categories of genetic alterations include changes in the behavior of
the malignant T-cell population and their imprint on the immune system, which
suggest clustering under three major pathways: constitutive T-cell activation (e.g.
STAT3, STAT5B, CARD11, CD28); resistance to apoptosis/cell cycle
dysregulation (e.g. MYC, FAS, CDKN2A, TP53, RB1); and DNA structural
dysregulation/chromatin remodeling or repair (e.g. ARID1A, DNMT3A) (Figure 1).

Figure 1: Pathways of the identified driver genetic alterations in CTCL
identified by exome sequencing. Genetic alterations in CTCL can grouped in
three categories: T-cell activation, cell cycle release/apoptosis inhibition, and
chromatic remodeling. Credit: Michael Girardi.
With this wellspring of new information, recently discovered and repurposed agents targeting pathways or specific gene mutations may be screened
as a patient-specific treatment algorithm is developed. With 30% of drugs in
clinical trials failing due to lack of efficacy, a focus on expanding indications of
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new molecular therapies allows us to leverage established safety profiles to fasttrack new treatment options for patients.39

Inhibition of Apoptosis, BCL2, and Venetoclax
One such opportunity for the repurposing of existing therapies involves the
dysregulation of B cell lymphoma-2 (BCL2) driven apoptotic pathways in CTCL.
The BCL2 family of proteins is a critical group of proteins involved in the
regulation of apoptosis. These proteins further regulate autophagy via the binding
of Beclin-1.40 BCL2 proteins are part of the intrinsic, or mitochondrial, apoptosis
pathway in which an apoptotic signal such as damage from free radicals or
growth factor starvation leads to programmed cell death (i.e. apoptosis) via
caspase activation. The apoptotic signal leads, via BCL2 family proteins, to the
permeabilization of the outer mitochondrial membrane, the release of cytochrome
c, and the subsequent activation of caspase.41,42 This is in contrast to the
extrinsic apoptotic pathway, in which death receptors activated by signals, such
as FAS-ligand or TNF-α, lead to caspase activation, or the perforin/granzyme
pathway, which leads to cell death by either caspase activation (granzyme B) or,
independent of capase, via direct DNA damage (granzyme A).43,44
The BCL2 family is traditionally defined by the presence of conserved
residue sequences known as BCL2 homology (BH) motifs, of which there are
four (BH1-4), though more recent findings suggests that BH motifs are not
essential to the function or characterization of BCL2 family proteins.45,46 The
BCL2 family can be divided up into three groups: the anti-apoptotic proteins (e.g.
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BCL2, BCL-XL, MCL1, BCL-w), the multiregion pro-apoptotic proteins (e.g. BAX,
BAK, BIK, BID) which are composed of multiple BH motifs, and the BH3-only proapoptotic proteins (e.g. BIM, BAD, NOXA, HRK, BLK, BMF, PUMA).41 The BH3only proteins may act in two ways: as a sensitizer, in which they bind to antiapoptotic proteins, or as activators, which may bind to either anti-apoptotic
proteins or the multiregion pro-apoptotic proteins.47 Twenty-five BCL2 family
proteins have been discovered to date.48
Anti-apoptoic proteins such as BCL2 or BCL-XL are mitochondrialmembrane bound or membrane bound upon activation. These proteins bind and
sequester the BH3- only pro-apoptotic proteins such as BIM. In the presence of a
death signal, the sensitizer BH3-only pro-apoptotic proteins (such as BMF) bind
to anti-apoptotic proteins (such as BCL2) releasing activator BH3-only proapoptotic proteins (such as BIM). These proteins then in turn bind to multidomain, pro-apoptotic proteins (such as BAX or BAK) which oligomerize to form
pores in the mitochondrial membrane, resulting in the release of cytochrome c
and caspase activation. The activation or inhibition of apoptosis depends on the
specific ratios of pro- and anti- apoptotic proteins.41
CTCL cells exhibit a high degree of resistance to apoptosis, even in the
presence of programmed-cell death inducing signals, and, as described above,
CTCL cells exhibit multiple genetic alterations which explain this behavior. Four
of the common gene alterations identified in CTCL are STAT3 amplifications,
STAT5B amplifications, and P53 deletions; the frequency of which was
previously validated by our group in the development of a new diagnostic tool, an
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11-gene FISH panel.49 Each of these mutations has been linked to the inhibition
of apoptosis through the up-regulation of BCL2 transcription, in turn leading to
increased BCL2 activity and dependence.50–57 Additionally point mutations have
been identified in the ITPR1 gene, which is associated with increased risk of
breast cancer, and involved in BCL2 activity and regulation.58 The tendency of
CTCL towards inhibition of apoptosis, and the putative trend towards increased
BCL2 activity in CTCL, makes inhibition of BCL2 an attractive therapeutic target.

Figure 2: Genetic alterations in CTCL, leads to increased BCL2 activity, and
resistance to apoptosis. STAT3 amplifications, STAT5B amplifications, P53
deletions, and Fas alterations result in decreased apoptosis.
Venetoclax (ABT-199) is a BH3-mimetic, BCL2 selective inhibitor without
additional cross-reactivity with BCL-XL, BCL-W, or MCL1.59 Venetoclax (ABT199) is a unique agent as a BCL2 inhibitor due to its specificity. Other so-called
“BCL2 inhibitors” available for research purposes are not specific for BCL2 as
they have been shown to also affect BCL-XL and/or MCL1. The most promising
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of these inhibitors was navitoclax (ABT-263) which showed impressive preclinical data in BCL2 dependent lymphoid malignancies. Further clinical
development of navitoclax was restricted due to dose-limiting thrombocytopenia
as a result of additional inhibition of BCL-XL, which is essential for platelet
survival. ABT-263 was thus re-engineered to bind exclusively to the BCL2
binding pocket, and clinical trials have borne out its potent efficacy in the
inhibition of BCL2. Venetoclax was first approved by the U.S. FDA in 2016,
received accelerated approval for the treatment of relapsed or refractory CLL
with 17p deletion, and is the only BCL2 inhibitor that has received approval by
the U.S. FDA for clinical use.60 Venetoclax is also currently undergoing trials for
follicular lymphoma, diffuse large B cell lymphoma, acute myeloid leukemia,
multiple myeloma, Waldenstrom macroglobulinemia, and NHL (excluding CTCL).

Figure 3: Mechanism of action of venetoclax (ABT-199). Venetoclax, as a
BH3 mimetic, binds with high affinity to BCL2, and causing dissociation of the
BCL2-BIM complex. BIM is then able to activate the pro-apoptotic protein BAX,
leading to oligomerization of BAX, permeabilization of the mitochondrial
membrane, and release of cytochrome c.
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The potential for BCL2 inhibition in the treatment of CTCL may extend
beyond its use as a monotherapy. Combined inhibition of BCL2 members and
HDACs has shown synergistic effects in CTCL61 and other malignancies,
including mantle cell lymphoma62 and glioblastoma.63 Romidepsin and vorinostat
are HDAC inhibitors64 which have widespread effects including modulation of
gene expression, induction of cellular differentiation, and modulation of apoptosis
effector genes.65 One mechanism of action of apoptosis is via alterations in the
expression of the intrinsic apoptosis pathway, namely the BCL2 family genes, 66–
69

including upregulation of pro-apoptotic factors such as BID and BIM, and down

regulation of the anti-apoptotic factors such as BCL-XL and MCL1.70–72
Through in vitro testing of CTCL patient-derived blood samples, we
demonstrate the potential of BCL2 inhibition by venetoclax as a novel treatment
for CTCL. Furthermore, we reveal that this effect is synergistically potentiated via
HDAC inhibition afforded by romidepsin or vorinostat. These results suggest that
BCL2 inhibition, alone or in combination with HDAC inhibition, represents a
viable novel strategy in the treatment of advanced CTCL with blood involvement.
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Statement of Purpose
Validate BCL2 as a potential target for the treatment of CTCL
Prior to my arrival in the Girardi Lab, Jason Weed (YSM 2017) led efforts
in designing and implementing an in vitro targeted dry testing platform for
leukemic CTCL, leading to the identification of several candidate drugs for further
testing, the most promising among which was venetoclax. We aim to test the in
vitro sensitivity of venetoclax on an expanded patient cohort in order to validate
BCL2 as a potential therapeutic target.

Associate expression of BCL2 family genes to the in vitro patient sample
sensitivity to venetoclax
In order to validate the putative mechanism of action of venetoclax in the
killing of CTCL cells—inhibition of BCL2—we sought to associate genetic
expression of BCL2 and other BCL2 family members to the sensitivity of
venetoclax. Additionally we sought to identify ratios of expression of BCL2 family
members that predict sensitivity to venetoclax.

Identify synergistic combinations of therapies
We hypothesize that drugs which alter genetic expression of BCL2 family
members, such as the HDAC inhibitors, vorinostat and romidepsin, will synergize
with venetoclax for more efficient killing of CTCL cells, with the hope that in
clinical practice, such combinations will limit both resistance and systemic
toxicities.
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Methods

Patient Samples
Blood samples were obtained from CTCL patients at the Yale Cancer
Center, receiving treatment either at the Yale Photopheresis Center or at the
Yale-New Haven Hospital Smilow Cancer Hospital. Written informed consent
was obtained from all subjects in accordance with the Yale Human
Investigational Review Board. Approximately 45 mL of peripheral blood was
obtained from consenting patients and healthy donors and collected in lithium
heparin tubes (BD Vacutainer). The whole blood was diluted in a 3:1 ratio with
phosphate-buffered saline (PBS), and peripheral blood mononuclear cells
(PBMC) were separated from whole blood using SepMateTM. 15 mL of Ficoll (GE
Healthcare Ficoll-Paque Premium) was placed at the bottom of SepMateTM-50
tubes and diluted blood was layered on top. The SepMateTM-50 tubes were then
centrifuged for 20 minutes at 1200g at room temperature. Buffy coats were
isolated and washed with PBS with 2% fetal bovine serum (FBS) in 15 mL
conical tubes, centrifuged for 8 minutes at 300g at room temperature,
resuspended in PBS with 2% FBS, rewashed in PBS with 2% FBS and
centrifuged again for 8 minutes at 300g at room temperature to minimize residual
Ficoll. The pellet was then re-suspended in RPMI and counted using
hemocytometer. CD4+ T-cells were selected by Miltenyi Biotec (Bergisch
Gladbach, Germany) MACS CD4+ negative selection kit per the manufacturer’s
protocol and supplemented with antibodies to select for CD26- and/or CD7- cells,
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depending on the known aberrant phenotype of the patient, as measured by the
patient’s most recent peripheral blood flow cytometry.
Aliquots of unfractionated PBMC and purified samples were obtained to
assess purity and verify expression of phenotypic markers. Additional aliquots of
purified samples (minimum 500 000 cells) were obtained and lyzed for RNA
analysis using Qiagen RNEasy (see below). Following isolation, cells were
cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS,
glutamine (2mM), penicillin (100μ/mL), and streptomycin (100μg/mL), as well as
IL2 (10ng/mL), IL7 (5ng/mL), IL15 (10ng/mL), and IL13 (10ng/mL; all cytokines
from R&D Systems) at 37°C, 5% CO2, and 95% humidity.

Cell Viability Assay
Following isolation of the desired cell population, cells were incubated in
quadruplicate at a density of 100cells/μL in 100μL of media, for a total of 10 5
cells/well, in a black optical 96-well plate. In order to limit effects from uneven
evaporation across the plate, cells were not plated in the exterior two rows of
wells, and instead filled with 100 μL of media. In order to ensure an equal
concentration of cells across the plate, cells were continuously mixed using
gentle pipetting throughout the plating process.
Cells were incubated for 72 hours with venetoclax (3 nM to 100 µM),
romidepsin (0.1 nM to 10 nM), and/or vorinostat (0.1 µM to 10µM). The CellTiterGlo® Luminescent Cell Viability Assay (Promega, WI, USA) was used to
measure the number of viable cells in culture based on quantitation of the ATP
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present. Plates were read using the Perkin Elmer Victor Light Luminescence
Counter (Waltham, MA, USA). Drug concentrations were applied in approximate
half-log10 increments to patient samples, and in 2-fold increments for cell lines.
Cell luminescence was normalized to a vehicle control containing 0.2% DMSO
and corrected for media.
Stocks of 50nM venetoclax, 20mM vorinostat, and 20nM romidepsin from
ApexBio (Houston, TX, USA) were prepared in DMSO and stored at -20°C.
Campthothecin (10μM) from Sigma (St. Louis, MO, USA) was used a positive
control for both the Viability Assay and the Caspase-3/7 Assay.

Caspase-3/7 Assay
Patient samples were incubated for 1-48 hours as described above in the
Cell Viability Assay. Following incubation, the Promega Caspase-Glo® 3/7 assay
(Madison, WI, USA) was used to quantitate caspase activity, as per the
manufacturer’s protocol. Plates were read using a Perkin Elmer Victor X Light
Luminescence Counter.

Flow Cytometry Analysis
Unfractionated PBMC and isolated malignant T-cell populations were
analyzed using flow cytometry. All samples were matched with an isotype
control. The following monoclonal antibodies were included: CD3 from BD
Biosciences (San Jose, CA, USA); CD4, CD7, and CD26 from eBioscience (San
Diego, CA, USA); and TCR-Vβ from Beckman Coulter (Brea, CA, USA). Cells
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were blocked with human TruStain FcX™ from BioLegend (San Diego, CA, USA)
for 10 minutes then incubated with selected antibodies for 20min at 4°C. Cells
were then washed three times and fixed in 1% paraformaldehyde. Flow
cytometry was conducted on the Stratedigm-13 from Stratedigm Inc. (San Jose,
CA, USA). All flow cytometric data were analyzed using FlowJo software (v10;
FlowJo, LLC).

Figure 4: Malignant cells negatively selected by magnetic bead sorting
based on the patient’s malignant phenotype

Cell Lines
MyLa 2059,73 Sez4,74 HH,75 and Hut7876 are well established CTCL cell
lines. MyLa 2059 and HH were cultured in RPMI 1640 medium supplemented
with 10% heat-inactivated FBS, glutamine (2mM), penicillin 100μ/mL, and
streptomycin (100μg/mL) at 37°C, 5% CO2, and 95% humidity. Sez4 was
cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS,
glutamine (2mM), penicillin 100μ/mL, and streptomycin (100μg/mL), as well as
IL2 (20ng/mL; R&D Systems) at 37°C, 5% CO2, and 95% humidity. Hut78 was
cultured in IMDM medium supplemented with 20% heat-inactivated FBS,
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glutamine (2mM), penicillin 100μ/mL, and streptomycin (100μg/mL) at 37°C, 5%
CO2, and 95% humidity. All media and supplements were obtained from
Invitrogen (Carlsbad, CA, USA).

Statistical analysis
For the Cell Viability Assay and Caspase-3/7 assays, each drug
concentration was performed in quadruplicate, and the mean values were plotted
with their respective standard deviation. The mean inhibitor concentration was
determined using GraphPad Prism (Version 7.01). Patient samples were grouped
using hierarchical clustering with Ward’s method77 in R (Version 3.0.1).
Combination index (CI) values and standard errors were calculated using the
Chou-Talalay method78 in Microsoft Excel.

Quantitative Real-Time Reverse-Transcriptase-PCR
RNA was extracted using the All-Prep DNA/RNA Micro Kit for patient
samples, or with the All-Prep DNA/RNA Mini Kit for cell lines from Qiagen
(Hilden, Germany) as per the manufacturer’s specifications. RNA was quantified
using the BioTek Epoch spectrophotometer. 2μg of RNA was converted to cDNA
using the High Capacity Reverse Transcription Kit from Applied Biosystems
(Foster City, CA, USA) per the manufacturer’s instructions. Patient cDNA
samples were then pre-amplified using the Applied Biosystems TaqMan® PreAmplification Master Mix as per the manufacturer’s instructions. Gene expression
was quantified using the TaqMan® primers and Gene Expression Master Mix
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and the Applied Biosystems 7500 Real Time PCR System. Samples were
characterized in duplicates. Obtained Ct values were normalized to HPRT1
expression and expression differences relative to healthy controls were
calculated using RQ = 2-ΔΔCt.
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Results

CTCL patient population and peripheral blood analysis
To begin to assess the potential of the BCL2 inhibitor venetoclax in the
treatment of CTCL with blood involvement (B1 or B2), peripheral blood samples
were obtained from 25 patients diagnosed with CTCL who have a malignant cell
population measured by flow cytometry. Patients were classified by their initial
diagnosis as erythrodermic/Sézary syndrome (13/25), mycosis fungoides (10/25),
or folliculotropic MF (2/25) (Table 1). Patient treatment statuses ranged from
extracorporeal photopheresis (ECP) with or without adjunct therapies (18/25), to
multimodal therapies (6/25), to cytoreductive therapy (1/25). Each patient
sampled underwent clinical flow cytometry, from which blood parameters were
calculated (Table 2). Patients were additionally tested for clonality by either PCR
based T-cell receptor (TCR) gene rearrangement studies or the presence of a
clonal Vβ antigen detectable by flow cytometry, with 25/25 patient samples
positive for clonality based on one or both tests. Eight patients were classified as
B1, and the remainder were classified as B2 based on the 2007 ISCL
classification14 and the 2016 Gibson et al. criteria.18

21
Table 1. Summary of CTCL patients’ peripheral blood flow cytometric
parameters. Abnormal cell phenotype identified by flow cytometry as
phenotypically atypical: TCR-Vβ positive if >50% of the population of atypical
cells express a single Vβ, or by indirect evidence, if there is less than 20%
expression of the entire 27 Vβ antibody panel.18 PCR positive if ≥1 of 3 PCR
reactions identifies a clone. B-stage based on ISCL classification14 and the 2016
criteria proposed by Gibson et al.18 Patients staged as B2 have elevated absolute
CD3+ or CD3+ CD4+ cell counts, with the upper limits of normal defined as
greater than 2245 cells/μl and greater than 1612 cells/ μl, respectively.
CD4+CD7- and CD4+ CD26- percent specifications are defined as percent of
peripheral blood mononuclear cells (lymphocytes and monocytes).
Pt
ID

Sorted Abnormal Cell
Population

TCR-Vβ +

Vβ gene
identified

PCR +

CD4/CD8
Ratio

CD4+
CD7- %

CD4+
CD26- %

Stage

1

CD3+ CD4+ CD7- CD26-

Yes

20

Yes

8.37

19.7

14.1

B1

2

CD3+ CD4+ CD26-

Yes

2

Yes

179.0

8.6

80.2

B2

3

CD3+ CD4+ CD26-

Yes

12

Yes

2.12

8.9

34.3

B2

4

CD3+ CD4+ CD7- CD26-

Yes

Indirect

No

8.11

14.3

38.5

B2

5

CD3+ CD4+ CD26-

Yes

16

Yes

15.6

10

71.5

B2

6

CD3+ CD4+ CD7- CD26-

Yes

1

Yes

28.69

86.2

84.5

B2

7

CD3+ CD4+ CD7- CD26-

Yes

13.6

None

56.81

83.9

58.7

B2

8

CD3+ CD4+ CD7- CD26-

Yes

12

Yes

24.78

54.9

71.4

B2

9

CD3+ CD4+ CD7- CD26-

N/A

N/A

Yes

10.22

38.9

36.5

B2

10

CD3+ CD4+ CD7- CD26-

Yes

13.1

Yes

7.06

44.3

25.5

B2

11

CD3+ CD4+ CD26-

Yes

13.6

Yes

9.66

11.4

46

B2

12

CD3+ CD4+ CD26-

Yes

Indirect

Yes

5.18

1.9

48.5

B2

13

CD3+ CD4+ CD7- CD26-

Yes

21.3

Yes

59.63

89.8

88.7

B2

14

CD3+ CD4+ CD26-

No

None

Yes

4.45

16.2

4.8

B1

15

CD3+ CD4+ CD7- CD26-

Yes

Indirect

Yes

6.95

63.9

62.6

B2

16

CD3+ CD4+ CD7- CD26-

Yes

Indirect

Yes

20.02

87.2

76.3

B2

17

CD3+ CD4+ CD7- CD26-

Yes

7.2

Yes

4.7

30.4

33.8

B2

18

CD3+ CD4+ CD7- CD26-

Yes

7.2

Yes

3.74

27.4

26.0

B1

19

CD3+ CD4+ CD7- CD26-

No

None

No

1.21

20.6

22.5

B1

20

CD3+ CD4+ CD7- CD26-

Suspicion

Indirect

Yes

1.63

22.5

24.5

B1

21

CD3+ CD4+ CD7- CD26-

Suspicion

5.3

None

4.75

69.6

71.8

B2

22

CD3+ CD4+ CD7- CD26-

Suspicion

17

Yes

1.75

19.9

18.5

B1

23

CD3+ CD4+ CD26-

Yes

2

Yes

27.91

51.1

89.5

B2

24

CD3+ CD4+ CD7- CD26-

Suspicion

Indirect

Yes

1.3

23.7

23.8

B1

25

CD3+ CD4+ CD7- CD26-

No

None

Yes

8.87

24.9

19.1

B1
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Table 2. Summary of patient characteristics.
Pt ID
1

Sex
M

Age
73

CTCL Subtype
FMF

Current Therapy
ECP

Previous Therapy
None
PUVA, ECP, vorinostat, MTX,
bexarotene, IFNα -2b, romidepsin,
gemcitabine/doxorubicin,
alemtuzumab,

2

M

84

SS

Brentuximab, vorinostat

3

M

66

SS

ECP

NB-UVB, topical steroids

4

M

85

SS

ECP

Topical steroids

5

F

71

SS

Gemcitabine

6

M

73

SS

Pralatrexate

7

F

61

SS

ECP, bexarotene

Topical steroids, phototherapy

8

M

77

SS

Romidepsin, vorinostat

ECP, NB-UVB

9

M

70

SS

Pralatrexate

Romidepsin, vorinostat,
mechlorethamine, ECP

10

M

71

MF

ECP, bexarotene

NB-UVB, topical steroids
Topical steroids

ECP, bexarotene, topical steroids,
IFNα-2b, vorinostat, romidepsin,
belinostat
Romidpesin, ECP, bexarotene,
topical steroids

11

F

79

SS

ECP, bexarotene,
vorinostat, INFα-2b

12

F

64

SS

ECP, bexarotene

Topical steroids

13

F

76

SS

ECP

None

14

M

61

MF

ECP, NB-UVB

None

15

M

67

SS

ECP, bexarotene

None

16

F

40

FMF

ECP, bexarotene

NB-UVB, TSEBT

17

M

66

SS

18

F

64

MF

19

M

87

MF

ECP

MTX, bexarotene, topical steroids

20

M

85

MF

ECP, bexarotene, NBUVB

Topical steroids

21

M

70

MF (V)

EPOCH

None

22

M

77

MF

ECP, bexarotene

NB-UVB, topical steroids

23

M

52

MF

Gemcitabine

NB-UVB, bexarotene, vorinostat,
ECP, IFNα-2b, Romidepsin,

24

F

62

MF

ECP, bexarotene, NBUVB, mechlorethamine

Topical steroids

25

M

62

MF

ECP, bexarotene

Topical steroids

ECP, bexarotene, NBUVB, topical steroids
ECP, bexarotene, IFNα2b, IFNγ-1b

None
None

Abbreviations: ECP, extracorporeal photopheresis; EPOCH, etoposide, prednisone,
vincristine, cyclophosphamide, doxorrubicine; F, female; FMF, folliculotropic mycosis fungoides;
IFN, interferon; M, male; MF, mycosis fungoides; MTX, methotrexate; NB-UVB, narrow band
ultraviolet-B; PUVA, psoralen ultraviolet light A; SS, Sézary syndrome; TSEBT, total body
electron beam therapy; V, visceral involvement.
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CTCL patient samples show highly variable sensitivity to venetoclax in vitro
We observed the cytotoxic/cytostatic effects of venetoclax in all 25 CTCL
patient samples after 72 hours of incubation as measured by the change in cell
viability via media ATP quantitation. Patient samples demonstrated a wide range
of sensitivities to venetoclax, with mean 50% inhibitory concentrations (IC50)
ranging from picomolar (85 pM) to micromolar (6.6 µM) levels. The observed
heterogeneity in sensitivity to venetoclax is not dissimilar to the variation
observed in T-ALL79 or CLL.59 The most sensitive samples compare favorably to
pre-clinical studies in B-cell lymphomas, the results of which have since been
validated via clinical trial.60. In order to better study the significance and origins of
the observed variation, we used hierarchical clustering based on their
responsiveness to venetoclax to divide the tested samples into two groups, low
and high responders. The majority of tested samples (20/25) were defined as
high responders with a group mean IC50 of 79.0 nM compared to the low
responders (5/25) with a group mean IC50 of 3.2 µM. Dose response curves for
three representative samples: the most sensitive, the median, and the most
resistant sample, are shown in Figure 5Bi.
Four established CTCL cell lines—MyLa 2059, Sez4, HH, and Hut78—
were also analyzed for sensitivity to venetoclax (Figure 5Bii). All four cell lines
demonstrated relatively low sensitivity to venetoclax with IC50s of 2.47 µM, 7.4
µM 10.2µM, and 33.6 µM respectively. In addition to the differences in IC50, cells
lines and patients were observed to have different patterns in their dose
response curves. Cell lines demonstrated a significantly higher Hill slope relative
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to patient samples (P<.0001) suggesting distinct mechanisms of action between
cell lines and patients (Figure 5C). Among patient samples, there was a
statistical trend noted between response status and Hill slope (P=.07; data not
shown). Hypothesizing an association between tumor burden and increased
sensitivity to induction of apoptosis via inhibition of BCL2, we compared the
mean inhibitory concentration of venetoclax between patients classified as B1
versus B2 (ISCL Classification)14, as well as between patients classified as
mycosis fungoides (non-erythrodermic) versus Sézary syndrome (erythrodermic),
and found a higher sensitivity in patients with more advanced disease, and in
patients with Sézary syndrome (Figure 5D,E).

25

Figure 5. Cell line and patient samples demonstrate variable sensitivity to
venetoclax. Isolated malignant cells from patient samples and 4 human-derived
CTCL cell lines were incubated with a range of concentrations of venetoclax for
72 hours from which IC50s and Hill slopes were calculated. The median and
mean IC50 for patient samples were 102nM and 833nM, respectively. (A) Patient
samples in order of IC50. Patients were grouped into high responders and low
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responders using hierarchical cluster analysis. (B) Representative dose response
curves for patient samples (Bi), and CTCL cell lines (Bii). (C) Comparison of Hill
slopes between patient samples and cell lines. The difference between them
would suggest distinct methods of actions. (D) Patient samples are most likely to
be sensitive to venetoclax in more advanced disease. Stage based on ISCL
classification.14 (E) Patient samples classified as Sézary syndrome (SS) are
more likely than mycosis fungoides (MF) patients to be sensitive to venetoclax.

Baseline BCL2 mRNA expression predicts in vitro sensitivity to venetoclax
To study the differences in response to venetoclax among both primary
patient samples and cell lines, the baseline genetic expression of four BCL2
family members was measured using quantitative RT-PCR and expressed
relative to the mean expression of the healthy controls (Figure 7A). Significant
differences were noted in BCL2 expression between high and low responders as
well as high responders and cell lines, while none were observed between low
responders and cell lines. Patient samples expressed lowers amounts of BCL2
than healthy controls, on average 29% less but this difference was not
statistically significant (P=.19). Also notable was the similar expression of
BCL2L1 (the gene encoding BCL-XL) among patient samples and cell lines, with
both sets demonstrating no difference relative to the healthy controls. Significant
differences were noted in the expression of BCL2L11 (the gene encoding BIM)
among cell lines, with high expression noted in Hut78, and low or undetectable
expression of BCL2L11 mRNA in the MyLa, Sez4, and HH lines (Figure 6A).
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Figure 6. Baseline Gene Expression. (A) Baseline BCL2L11 expression in the
four tested CTCL cell lines, MyLa, HH, and Hut78, measured as a fraction of
healthy controls. BCL2L11 expression was not detected in the HH cell line after
40 cycles of RT-PCR. (B) Baseline expression of BCL2L1, BCL2L11, MCL1 and
BAX in primary patient samples did not correlate to sensitivity to venetoclax.

For the 20 patient samples examined, IC50 values were plotted as a
function of relative expression of BCL2 member mRNA. While a negative
correlation was found between baseline expression of BCL2 and IC50
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(Spearman r= -0.52, P= .018) (Figure 7B), mRNA expression of other BCL2
family members (BCL2L1, MCL1, BCL2L11, BAX) did not correlate with the IC50
values (Figure 6B). Furthermore, we examined ratios of expression of BCL2 to
the other tested BCL2 family members and found that higher ratios of BCL2 to
BCL2L1 correlate with greater sensitivity to venetoclax in vitro, while ratios of
BCL2 to MCL1 and BCL2 to BCL2L11 do not (Figure 7C). These results point to
the importance of both BCL2 and BCL2L1 expression, and indeed relative
expression of one another, to the survival of malignant T-cells. Additionally, the
limited correlations of both BCL2 and the BCL2/BCL2L1 ratio to sensitivity
suggest that a more complex relationship between BCL2 expression and
inhibition of apoptosis may exist.

Figure 7. Baseline gene expression of BCL2 family members and
correlation to IC50. BCL2, BCL2L1, MCL1, and BCL2L11 were measured in 20
patient samples, 4 cell lines and 3 healthy controls. Results are expressed as a
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fraction of the mean of the healthy controls. (A) Baseline expression of BCL2 was
found to differ significantly between high responders and low responders. No
difference was found between low responders and cell lines. BCL2L1 was
expressed similarly among all four groups. Decreased MCL1 expression was
noted in cell lines compared to patient samples. (B) BCL2 mRNA expression may
predict response to venetoclax in vitro, with higher expression correlating to
increased sensitivity. (C) Increased ratios of expression of BCL2 to BCL2L1
predicts higher sensitivity to venetoclax.

Combination inhibition of BCL2 and histone deacytelase results in synergistic
killing of CTCL cells from patient samples
Fifteen of the CTCL patient samples were tested for synergy between
venetoclax and two HDAC inhibitors, vorinostat and romidepsin. Each of the
three drugs was tested individually and in combination and IC50 values and Hill
slopes were calculated. From these dose response curves, the combination
index (CI) was calculated using the Chou-Talalay method in Microsoft Excel, with
a CI<1 indicating a synergistic interaction80. For combinations of venetoclax with
either HDAC inhibitor, synergy was observed at the higher dose range (Figure
8A,B).
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Figure 8. Combinations of venetoclax with either romidepsin or vorinostat
demonstrate synergy in patient derived cultures. (A) Viability curves for
venetoclax, vorinostat and their combination for Patient 11. After 72 hours of
incubation the viability curves and the combination index were calculated using
the Chou-Talalay median-effect equation. Means of the quadruplicates are
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shown with standard deviations. (B) Viability curves for venetoclax, romidepsin
and their combination for Patient 11. (C) CI and fitted curves for the combination
of venetoclax and vorinostat for Patient 11. (D) CI and fitted curves for the
combination of venetoclax and romidepsin for Patient 11. (E) Caspase-3/7
activation after 24 hours of incubation of the cell culture derived from Patient 11
with venetoclax, vorinostat, romidepsin and their combinations. All concentrations
were studied in quadruplicate and plotted are the means with their respective
standard deviations. (F) A significant increase in activation of caspase is seen in
higher concentration combinations. Effects are similar for combinations of
venetoclax with either vorinostat (Fi), and romidepsin (Fii).

93% of tested samples demonstrated synergy of response with combinations of
venetoclax and vorinostat at 10% viability (0.9 fraction affected), while 73%
demonstrated synergy of response between venetoclax and romidepsin (Figure
8C,D; Figure 9A; Table 3). No correlation was found between either expression
of BCL2 or sensitivity to venetoclax and the degree of synergy (data not shown).
Additionally, no differences were found between mycosis fungoides patients or
Sézary syndrome patients and degree of synergy, for combinations of venetoclax
with either HDAC inhibitor (Figure 9Bi,ii).
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Figure 9. Summary of Combination Index data. For each of the 15 patient
samples tested for synergy between venetoclax and either vorinostat or
romidepsin the combination index was calculated at 10% viability (0.9 fraction
affected). No correlation was found between the combination index and the
diagnosis at original presentation. Each patient was classified as either Sezaré
Syndrome (erythrodermic) or mycosis fungoides (non-erythrodermic).
In order to investigate the mechanism of action, the induction of apoptosis
at 24 hours was measured by caspase 3/7 activation. Dose response curves
were again produced for venetoclax, vorinostat, and romidepsin individually and
in combination. The effect of combination therapy upon caspase 3/7 activity
displayed a dose-dependent action (Figure 8E). Our measurements of caspase
activation support the observations made with the cell viability assay regarding
the form of interaction between venetoclax and the HDAC inhibitors, in which
there are disparate effects at low and high drug concentrations. At low doses of
venetoclax and either HDAC inhibitor, antagonism was observed. In contrast, we
observed a significant increase in caspase 3/7 activity with combination therapy
compared to either drug alone at high doses (Figure 8F).
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Table 3: Calculated combination index at 10% viability (0.9 fraction affected) for
each tested patient sample. Synergistic interactions are noted in green, while
antagonistic interactions are noted in red, as per the legend (Adapted from
Chou78). 93% of samples displayed synergy between venetoclax and vorinostat.
73% of samples demonstrated synergy between venetoclax and romidepsin.

Drug IC50 [nM]

Combination Index at 10% Viability (± SEM)

Pt #

Venetoclax

Vorinostat

Romidepsin

Venetoclax + Vorinostat

Venetoclax + Romidepsin

2

6.467

2569

2.310

0.75 ± 0.09

0.50 ± 0.05

3

9.607

1254

1.515

0.05 ± 0.24

0.24 ± 0.06

4

12.11

57.17

7.927

0.13 ± 0.05

0.90 ± 4.10

5

15.06

1813

6.759

0.63 ± 0.09

1.34 ± 0.20

6

15.98

2032

15.15

0.39 ± 0.06

0.62 ± 0.07

7

18.95

2202

2.066

1.75 ± 0.16

1.43 ± 0.29

8

22.86

1531

1.245

0.52 ± 0.07

0.78 ± 0.20

10

51.25

1468

1.764

0.92 ± 0.38

0.90 ± 0.27

11

67.19

4761

4.163

0.32 ± 0.03

0.30 ± 0.03

12

99.1

1486

8.556

0.59 ± 0.14

1.07 ± 6.28

13

102

2260

2.138

0.44 ± 0.10

0.58 ± 0.21

14

115.1

465.7

1.867

0.84 ± 0.22

0.40 ± 0.08

15

128.9

1266

3.884

0.57 ± 0.46

3.45 ± 29.51

21

1040

2160

1.357

0.67 ± 0.24

0.42 ± 0.10

23

2891

5387

2.577

0.65 ± 0.21

0.62 ± 0.49

% Synergistic

93

73

Synergy studies were similarly performed on the cell lines (Figure 10). The
only cell line to display significant synergy was MyLa 2059 when venetoclax was
combined with vorinostat. In both the HH and Hut78 cells, venetoclax and
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vorinostat had antagonistic responses. In combinations of venetoclax and
romidepsin, only the HH cell line demonstrated synergistic sensitivity. Unlike the
response of patient cells which are well modelled by the Hill and median-effect
equations, the cell lines display significant deviations from the expected
responses, especially at high doses. This may be attributed to the heterogeneity
of the cell lines, which are not necessarily clonal, or to the highly cytotoxic effects
of drugs such as romidepsin at higher doses.26,81 Thus, our ability to detect
synergy at these dose ranges is limited.

Figure 10. Searching for synergy in CTCL cell lines. Four CTCL cell lines
were tested for synergy between venetoclax and vorinostat, and between
venetoclax and romidepsin. Cell lines were first incubated with incremental
increase of each of the three drugs individually to calculate IC50 values. Next cell
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lines were incubated with combinations of each drug in an approximate 1:1 ratio
of the calculated IC50 values. Synergy was noted between venetoclax and
vorinostat in the MyLa cell line and between venetoclax and with high doses of
romidepsin in the HH cell line.
BCL2 family member expression changes in response to HDAC inhibition
To provide insight into the mechanism of action of synergy and
antagonism between venetoclax and the HDAC inhibitors romidepsin and
vorinostat, we incubated the four CTCL cell lines for 24 hours with 5μM vorinostat
or 5nM of romidepsin before isolation of RNA and measured the relative
expression of 7 BCL2 family members compared to a DMSO vehicle control via
qRT-PCR (Figure 11A). Following exposure to vorinostat there was a 40-fold
increase in BCL2L11 expression and a 12-fold increase in BMF expression. The
dramatic increase in BCL2L11 mRNA is critical to the function of BCL2, which
acts to inhibit apoptosis via direct binding to BIM. This shift in balance towards
pro-apoptotic factors is not only one of the methods of action of vorinostat, but
sheds light on interactions between venetoclax and HDAC inhibition.
Furthermore, we were able to detect a statistically significant trend between the
change in expression of BCL2 in response to vorinostat and the calculated
combination index at a fraction affected of 0.9 (Figure 11B). MyLa, the only cell
line in which BCL2 expression was increased, was the only cell line to
demonstrate significant synergy. Romidepsin caused a 13-fold increase in BMF
and 4-fold increase in BCL2L11 expression. No significant changes in expression
of BCL2 were noted following exposure to romidepsin in any of the three cell
lines.
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Figure 11. Changes in genetic expression of BCL2 family members
following incubation with vorinostat or romidepsin. (A) Significant changes
include the increased expression of BCL2L11, BMF, and MCL1. Notable is the
2.7-fold increase in BCL2 expression in the MyLa cell line with vorinostat. (B) The
amount of calculated synergy, represented by the combination index at 0.9
fraction affected (10% viability) was correlated to change in expression of BCL2
after 24 hours of incubation with 5µM vorinostat, a strong correlation was noted,
but only limited conclusions can be drawn, due to the small sample size.
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Discussion
Guided by recent studies5,27,82–85 that suggest that increased resistance to
apoptosis in CTCL is at least partly due to gene alterations that may increase the
transcription of BCL2, and encouraged by the success of venetoclax in the
treatment of CLL,86 we sought in this study to explore the potential of venetoclax
for the treatment of CTCL. We identified a group of patients, the high responders,
with exquisite sensitivity to venetoclax at a mean IC50 of 79.0 nM. This range is
comparable to the range of sensitivities, <300 nM previously observed in BCL2
dependent immature CD4- CD8- T-ALL subtypes. Three clinical trials87–89
investigating the treatment of CLL and NHL found the maximum plasma
concentrations for 400mg, 800mg, and 1200mg to be 2.2µM, 3.5µM and 4.0µM.
These values far exceeded the in vitro mean inhibitory concentrations observed
in our study. We are further encouraged as the maximum tolerated dose of
venetoclax has not yet been well established, necessitating dose escalation
beyond 1200mg.90,91 Indeed, the most significant adverse events in the trials for
CLL were deaths due to tumor lysis syndrome.92
Having established the response of primary patient samples to venetoclax
in vitro, we next searched for a biological assay that would predict sensitivity and
distinguish high responders from low responders. BCL2 protein and mRNA
expression have been found to have an inverse relationship with sensitivity to
venetoclax in vitro CLL,93 NHL,59 and T-ALL.79 Our data indicates that a similar
relationship exists in CTCL, additionally supported by the significant difference in
expression of BCL2 among high and low responders. Other work has shown that
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expression of BCL2L1 and MCL1 contribute to resistance to venetoclax,60,70,72,94
but our work suggests that higher expression of either at baseline does not
correlate with sensitivity in the patient samples tested.
Previous work79,95,96 with T-ALL has identified a wide variation in response
to venetoclax among cell lines and primary patient samples, wherein T-ALL cells
displaying the immature phenotypes CD4- CD8-, such as LOUCY cell line,
exhibit BCL2 dependence, and correspondingly submicromolar sensitivity in vitro
to venetoclax. In contrast, cell lines with mature phenotypes demonstrate
dependency for survival on the protein BCL-XL, and decreased sensitivity to
venetoclax with greater than 1μM IC50 values. CTCL itself has been
characterized by TCR sequencing97 as a disease derivative of mature memory Tcells, from which one would predict dependency on BCL-XL. Direct
measurements of mitochondrial membrane depolarization98,99 have highlighted
the stark differences in responses to BH3 mimetics between BCL2 and BCL-XL
survival-dependent cells. A recent study100 looked at the BH3 profiles of T-cell
lymphomas cell lines, including two examined in our study, MyLa and Hut78. The
two cell lines were identified as BCL-XL dependent, which was confirmed in our
study, as we measured similar expression of BCL2L1 in all three cells as well as
significantly decreased expression of BCL2 and MCL1, relative to normal
controls. These findings, along with our observation of poor sensitivity of the
three cell lines to the BCL2 selective inhibitor venetoclax, suggest that some
CTCL cases are BCL-XL dependent. This interplay of BCL2 and BCL-XL was
additionally significant in primary patient samples where the majority of samples
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had a higher expression of BCL2 than BCL2L1, and a larger ratio predicted of
sensitivity to venetoclax.
Synergy has been described between BCL2 inhibitors with a number of
different therapies and in numerous malignancies.62,63,79,95,101–104 Here, we show
evidence of synergy between venetoclax and two HDAC inhibitors vorinostat and
romidepsin. Synergy was consistently observed at the higher dose ranges of
either HDAC inhibitor indicating a dose-dependent mechanism. Not only did we
detect antagonism at low doses, but there was some evidence of direct inhibition
of caspase 3/7 activity with administration of either HDAC inhibitor alone. This is
consistent with reports on both romidepsin66 and vorinostat105 which showed the
effects of either drug differ dramatically at low and high dose, including one study
where romidepsin was found to inhibit the production of reactive oxygen species
at low doses.68
The lack of synergy observed in the CTCL cell lines suggests, perhaps
unsurprisingly, that expression of and dependence on BCL2 is required for
synergistic interactions with other therapies. While in the cell lines the observed
synergy can be linked directly to changes in BCL2 expression, the preferential
effect observed with vorinostat and venetoclax is likely due to the greater degree
of change in the expression of BCL2L11. Dissociation of BCL2-BIM complexes
have been implicated as the primary mechanism of induction of apoptosis by
venetoclax and other BCL2 inhibitors.21, 46, 68 The low baseline expression of
BCL2L11 in the HH and MyLa cell lines further supports the proposed theory that
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change in expression of BCL2L11 is critical to apoptosis by romidepsin, while
baseline expression is non-essential to therapeutic effects.107,108
In summary, this study supports the clinical implementation of venetoclax
as a novel therapy for leukemic CTCL, and further demonstrates a synergistic
effect when venetoclax is combined with the HDAC inhibitors romidepsin and
vorinostat. The potential for an effective combination oral therapy with venetoclax
and vorinostat is also intriguing. Further clinical trials are planned to explore this
potential synergy in vivo.
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Appendix
Transplantation in the Treatment of Primary Cutaneous Aggressive
Epidermotropic Cytotoxic CD8 Positive T-Cell Lymphoma
(Published in Clinical Lymphoma, Myeloma & Leukemia 2017)
Benoit M. Cyrenne, Juliet Fraser Gibson, Antonio Subtil, Michael Girardi, Iris
Isufi, Stuart Seropian, Francine Foss

Abstract
MicroAbstract: Several studies have suggested that hematopoietic stem cell
transplant (HSCT) may provide a cure for Primary Cutaneous Aggressive
Epidermotropic Cytotoxic CD8 positive T-Cell Lymphoma (CD8+ PCAETL). We
summarize published literature on this disease and present outcomes of 8
patients with CD8+ PCAETL treated at our institution. In our experience,
allogeneic HSCT and the novel agents brentuximab and pralatrexate
demonstrate substantial activity against this disease.

Structured Abstract:
Background: Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8
positive T-Cell Lymphoma (CD8+ PCAETL) is a rare subtype of peripheral T-cell
lymphoma with poor outcomes and without a standardized treatment strategy.
Allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested
as a potential curative therapy.
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Methods: We conducted a retrospective case series. We identified eight patients
with the diagnosis of CD8+ PCAETL, four of whom also underwent allogeneic
HSCT.
Results: Eight patients were treated at our center with combination
chemotherapy and several novel agents, including HDAC inhibitors,
Brentuximab, and Pralatrexate. Patients underwent a median of 8.5 treatments
prior to HSCT. Six of the eight patients examined, including all four who received
a HSCT, were alive at their last follow up.
Conclusion: Allogeneic HSCT is a promising treatment modality for CD8+
PCAETL. Given the aggressive nature of this disease and lack of sustained
remission with currently available therapies, HSCT should be considered early in
the course of treatment. Two novel agents, brentuximab and pralatrexate,
demonstrated significant activity against CD8+ PCAETL, and may be
incorporated earlier in the treatment course.
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Introduction1
Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 positive TCell Lymphoma (CD8+ PCAETL) comprises 1% of all cases of cutaneous T cell
lymphomas. The disease was given provisional status under the umbrella
category Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS), in
the 2005109, 2008110, and 2016111 WHO-EORTC classifications. The disease
remains a diagnostic challenge as subtypes may lack markers such as CD8 and
the αβ-TCR112–114 originally thought to be essential to the diagnosis, and due to
histopathologic mimickers of the disease such as lymphomatoid papulosis Type
D115. PCAETL is characterized by disseminated ulcerative lesions, frequent
extra-cutaneous involvement, and a high mortality rate. There exists no
standardized treatment algorithm and treatment strategies vary widely among
centers. Several studies and case reports have suggested that hematopoietic

Abbreviations: AE, adverse effects; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin;
AWD, alive with disease; AWOD, alive without disease; BEAM, carmustine, cytarabine,
etoposide, melphalan; BMT, bone marrow transplant; BTX, bexarotene; Bu, busulfan; CD8+
PCAETL, Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 positive T-Cell
Lymphoma; CHASE, cylophosphamide, cytosine arabinoside, etoposide, and dexamethasone;
CHOEP, cylophosphamide, adriamycin, vincristine, etoposide, prednisone; CHOP,
cylophosphamide, adriamycin, vincristine, prednisone; CR, complete response; D, dead;
DICE, dexamethasone, ifosfamide, cisplatin, etoposide; DHAP, dexamethasone, cytarabine,
cisplatin; DLI, donor lymphocyte infusion; DOL, death of lymphoma; ECP, extracorporeal
photopheresis; EORTC, European Organisation for Research and Treatment of Cancer; EPOCH,
etoposide, prednisone, vincristine, cyclophosphamide, doxorrubicine; F, female; Flu, fludarabine;
Gem, gemcitabine; GVHD, graft versus host disease; HDAC, histone deacetylase; HSCT HyperCVAD, cyclophosphamide, vincristine, doxorubicine hydrochloride, dexamethasone; ICE,
ifosfamide, carboplatin and etoposide; M, male; MCEC, ranimustine, carboplatin, etoposide,
cyclophosphamide; MIDLE, methotrexate, etoposide, ifosfamide, mesna, l-asparaginase; MTX,
methotrexate; mo, months; N/A, not applicable; ND: Not Documented; NM, nitrogen mustard NR:
No Response; PD, progressive disease; PPX, prophylaxis; PR, partial respone; ProMACECytaBOM, cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine,
methotrexate and prednisone; PTX, pralatrexate; PUVA, psoralen ultraviolet light A; Romi,
romidepsin; SCT, stem cell transplant; SMILE, dexamethasone, methotrexate, ifosfamide, Lasparaginase, etoposide; TBI, total body irradiation TSEBT, Total skin electron beam therapy;
UCTH1, anti-human CD3; WHO, World Health Organization; XRT; radiation therapy; y, years.
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stem cell transplant may represent a definitive, and potentially curative
therapy112,116,117. In this review we present our single-center experience of eight
cases of CD8+ PCAETL, including 4 who underwent allogeneic stem cell
transplantation, and a review of 18 published cases describing the use of
transplant in these patients.
Methods
We performed a retrospective analysis of all patients with the diagnosis of
CD8+ PCAETL treated at the Yale-New Haven Hospital between 2007 and 2017.
Patients were included in the analysis if they met the clinical, histopathologic, and
molecular criteria for CD8+ PCAETL defined by the 2016 WHO classification,
including an epidermotropic proliferation of abnormal cytotoxic CD8+
lymphocytes. Two patients were previously reported as a part of a larger case
series112. Immunohistochemistry was obtained and included antibodies against
the following: CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD30, CD56, β-F1 TIA-1,
and/or granzyme B. Demographic information, symptoms, treatment, outcome,
and follow-up information were obtained and documented in Tables 1, 2, and 3.
Yale University’s Institutional Review Board granted exempt status for this
retrospective case series.
We conducted a review of the literature to identify previously reported
cases where bone marrow or stem cell transplants were used for the treatment of
CD8+ PCAETL. A MEDLINE (Ovid), Embase (Ovid), and Web of Science search
was performed using the search words “Primary Cutaneous Aggressive
Epidermotropic Cytotoxic CD8 positive T-Cell Lymphoma”, and the key words
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“Cutaneous T-Cell Lymphoma”, along with “bone marrow transplant”, “allogeneic
stem cell transplant”, “autologous stem cell transplant”, and “stem cell
transplant”. Additional cases were identified using citation searches. A total of 18
cases were identified (Table 5).112,118–128

Results
Patient Characteristics
We identified eight cases with a diagnosis of CD8+ PCAETL. A complete
list of patient characteristics can be found in Table 1. The median age at time of
diagnosis was 53 years (range 20 to 77 years). The most common clinical skin
presentation was with multiple ulcerated lesions, with one patient unique in only
having a single lesion, and another with no ulceration. Lesions were either
patch/plaque or tumors, with two patients presenting with both. PET scanning
demonstrated FDG avid lymphadenopathy in 5 of 8 patients. One patient had
lymph node involvement confirmed by biopsy. A single patient presented with
visceral involvement, with diffuse metastasis, including the brain. Bone marrow
involvement was done in 5 patients and none showed involvement. Three of
eight patients had presence of circulating neoplastic cells on flow cytometry.
Pathology
Pathology was consistent among the 8 patients and included presence of
epidermitropism and atypical lymphocytes with hyperchromatic nuclei. Invasion
of hair follicles was noted in 2 of 8 patients, though hair follicles were not present
in all samples. Acanthosis was noted in 2of 8 biopsies. Necrotic keratinocytes
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with frank ulceration were seen in 4 of 8 samples. Infiltrates extended into the
dermal papillae (3 of 8), superficial (5 of 8), mid (3 of 8), deep dermis (2 of 8),
and superficial panniculus (1of 8). Red cell extravasation and mild vascular
ectasia were seen in 3 of 8 biopsies. Both small/medium lymphocytes (4 of 8)
and large lymphocytes (4 of 8) were noted.
Immunophenotyping was performed on all samples (Table 3, 4). All 8
samples were found to be CD3+, and the majority (7/8) were CD8+ as well. This
includes one sample that was found to be positive for both CD4 and CD8. One
patient was CD4- and CD8-, though otherwise pathologically identical to the
other samples. Samples showed variable expression of CD2, CD5, and CD7. In
all samples TIA-1 (7/7) and granzyme (2/2) were expressed. All samples that
were tested were positive for the cytotoxic marker β-F1, and negative for γδ
surface markers.
Treatment and Outcome
Treatment and outcomes for the 8 patients are summarized in Table 1 and
3, and more detailed information can be found for each individual patient in Table
4. Systemic chemotherapy was used in all but one patient. The only patient not to
receive systemic therapy was the only patient without multiple, disseminated
lesions. The tumor in this patient regressed following radiation therapy to the
area. Other complete responses were achieved with total skin electron beam
therapy (TSEBT) (1/4), allogeneic stem cell transplantation (SCT) (3/4),
adriamycin, vincristine, prednisone (CHOP) chemotherapy (1/2), vincristine,
doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy (1/4),
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gemcitabine based chemotherapy (1/5) and brentuximab therapy (1/4); however,
durable responses were observed only with allogeneic SCT or brentuximab
therapy. Of the 4 patients who were treated with brentuximab vedotin, 3 had
CD30 staining in their tumor cells and the fourth was CD30 negative. Of the four
patients who received an allogeneic SCT, two received a matched-related donor
(MRD) transplant, one received an unrelated donor (URD) transplant, and one
received a double unrelated umbilical cord blood transplant. One patient received
two donor lymphocytes infusions. Conditioning among the four patients was
either reduced intensity conditioning with fludarabine and buslfan (1/4), or
standard myeloablative therapy with total body irradiation (1/4) with either
pentostatin (1/4) or fludarabine and cyclophosphamide (1/4). Six patients remain
alive, including all four who received a SCT. Four patients with active disease are
on salvage chemotherapy and two are without evidence of disease. Of the two
patients who died, one died as a result of complications from lymphoma with
diffuse visceral involvement, and one due to sepsis. The median follow-up time
was 40 months (range 6 to 57 months).
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Tables
Table 1: Patient Cohort Characteristics
Variable
n (%)
Sex (female, male)
5, 3
Median age, y (range)
53 (20-77)
Presentation
Single Lesion
1 (12.5%)
Multiple Lesions
7 (87.5%)
Patch/plaque
6 (75%)
Tumor
4 (50%)
Ulceration
7 (87.5%)
Lymphadenopathy
5 (62.5%)
Visceral Involvement
1 (12.5%)
Bone marrow involvement
0 (5) (0%)
Circulating tumor cells
3 (37.5%)
B symptoms
0 (0%)
LDH elevated
1 (12.5%)
Therapies
Median number of therapies
8.5 (1-13)
(range)
Chemotherapy
7 (87.5%)
CHOP
2 (25%)
EPOCH
4 (50%)
DICE
1 (12.5%)
Hyper CVAD
1 (12.5%)
DHAP
2 (25%)
SMILE
1 (12.5%
MIDLE
1 (12.5%)
Gemcitabine
5 (62.5%)
Pralatrexate
5 (62.5%)
Bendasmutine
2 (25%)
Vinorelbine
2 (25%)
HDAC inhibitors
6 (75%)
Brentuximab
4 (50%)
UCHT1
1 (12.5%)
Denileukin Diftitox
3 (37.5%)
Alemtuzumab
1 (12.5%)
Pembrolizumab
1 (12.5%)
TSEBT
4 (50%)
Radiation
2 (25%)
Allogeneic Transplant
4 (50%)
DLI
1 (12.5%)
Status at Last Follow-up
Alive without disease
2 (25%)
Alive with disease
4 (50%)
Dead of lymphoma or
2 (25%)
complications
Median follow-up time, mo
40 (6-171)
(range)
Overall Survival
75%
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Table 2: Patient Cohort Pathology
Immunophenotype
Number
Markers
positive (n)
CD2
2 (7)
CD3
8 (8)
CD4
1 (6)
CD5
4 (6)
CD7
3 (6)
CD8
7 (8)
CD30
2 (6)
TIA-1
7 (7)
Granzyme B
2 (2)
γδ-TCR
0 (6)
β-F1
6 (6)

%
29
100
17
67
50
88
33
100
100
0
100

Table 3: Summary of Treatment Response
Treatment
Number of patients with Documented
Response, either SD, PR, or CR (n)
EPOCH
3 (4)
Gemcitabine
4 (5)
Pralatrexate
3 (5)
HDAC Inhibitors
0 (6)
Brentuximab
4 (4)
TSEBT
3 (4)
Allogeneic SCT
2 (4)

%
Response
75%
80%
60%
0%
100%
75%
50%
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Table 4: Individual patient immunophenotype, treatment, outcome, current status
Pt

Age at
diagnosis, y

Immunophenotype

Treatment and Response

1

36

Positive: CD3, CD4, CD8,
CD30, TIA-1, Granzyme-B
Negative: ND

CHOP (PR), bexarotene (PR), Vorinostat (PD), TSEBT (PR),
Denileukin Diftitox (PR), gem/vinorelbine/doxorubicin (PR, d/c due to
AE), EPOCH (PD), Romidepsin (PD), PTX (PD),
Brentuximab/cyclophosphamid/adriamycin/
prednisone (PR), HSCT (CR)

2

77

Positive: CD3, CD8, TIA-1,
β-F1
Negative: CD2, CD4, CD5,
CD7, CD20, CD30, CD56

XRT (CR)

3

52

Positive: CD3, CD5, CD8 ,
TIA-1, β-F1
Negative: CD2, CD4, CD7,
CD30

PTX (PR), XRT (PR), gem/doxorubicin (PR), TSEBT(PD), romidepsin Allogeneic
(PD), ICE (PD), CHOP (CR), HSCT (relapse), bendamustine and
brentuximab (SD)

4

54

TSEBT (PR), ECP (PD), Hyper-CVAD (PD), DICE (PD), XRT (PD)

DOL

5

61

Positive: CD3, CD8
Negative: CD2, CD5
Positive: CD2, CD3, CD5,
CD7, CD45RO, CD56, TIA1
Negative: CD4, CD8

TSEBT (PR), PTX (PD), EPOCH (PR)

AWD

6

50

7

20

8

65

Positive: CD2, CD3, CD8,
Vorinostat (PD), romidepsin (PD),
TIA-1, β-F1
denileukin diftitox/bexarotene (PR), gem (PD),
Negative: CD4, CD7, CD30 alemtuzumab (PD), brentuximab (PR, d/c due to AE), peginterferon/mechlorethamine (PD), PTX (PR), pembrolizumab (PD)
Positive: CD3, CD5, CD7,
PTX (PR), romidepsin (PD), gem (PD), UCHT1 (PD), EPOCH (PR),
CD8, TIA-1, β-F1
bendasmutine (PD), DHAP (SD), TSEBT (CR), MIDLE (PR),
Negative: CD2, CD4, CD30 gem/vinorelbine/doxorubicin, HSCT (CR)
Positive: CD3, CD5, CD7,
CD8, CD30, TIA-1,
Granzyme B,
Negative: CD2, CD4

EPOCH (CR), romidepsin (PD), cyclophosphamide (PD),
gem/oxaliplatin (CR), HSCT (relapse), EPOCH (PD), DHAP (PD),
DLI (PD), brentuximab (CR)

BMT

Conditioning

Current
Status

Allogeneic

Flu/BU

AWD

AWD

TBI

AWD

D, sepsis

Allogeneic

Cyclophosphamide AWOD
/flu/TBI

Allogeneic,
DLI

Pentostatin/TBI

AWOD
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Table 5: Summary of cases from literature
Reference

n

Agnarsson,
1990118

2

Type of
Age, Sex
transplantation years
Autologous

38

F

Autologous

62

F

Sx if specified

Immunophenotype

Previous
Treatment

Conditioning

RR

Response
duration,
months
ND

GVHD PPx

ND

Current
Status/Follow-up
Information
Relapsed, treated with
PUVA, alive with stable
disease 36mo after
diagnosis

Widespread
papulonodules;
chronic patches
and psoriasiform
plaques
Widespread
papulonodules;
chronic patches
and psoriasiform
plaques
Widespread
patches, plaques,
papulo-nodules,
tumors, necrotic
lesions
Generalized
ulcerative lesions

Positive: CD3, CD5, CD7,
CD8, Ia
Negative: CD2, CD4, CD25,
CD30, T9

Interferon alfa 2b,
topical NM, MTX

ND

CR,
relapse

Positive: CD3, CD5, CD7,
CD8, Negative: CD2, CD4,
CD25, CD30, T9, Ia

Topical NM,
TSEBT, isotretinoin,
interferon alfa-2b

ND

CR,
relapse

ND

ND

Died 50mo after
diagnosis

Positive: CD3, CD7, CD8,
CD45RA, TIA-1, TCR-β
Negative: CD1a, CD2, CD4,
CD5, CD25, CD30, CD45RO,
Granzyme B, Perforin
Positive: CD3, CD7, CD8,
CD25, TIA1, perforin, TCR-β
Negative: CD2, CD4, CD20,
CD30, CD56

Interferon alfa ,
ProMACECytaBOM

ND

NR

0

ND

Cyclophosphamide,
TBI

CR

17 mo

Tacrolimus,
MTX

Following BMT treated
with TSEBT without
response. Succumbed
to disease 20mo after
diagnosis
GVHD with total-body
desquamation, resolved
with oral prednisone

Berti,
119
1999

1

BMT

31

M

Liu, 2007120

1

Allogeneic

44

F

Webber,
2010121

1

Autologous

38

M

Extensive
ulcerative
plaques and
tumors

Positive: CD8, CD45A, β-F1
Negative: CD2, CD4,
CD45RO

PUVA, interferon
alpha, acitretin,
XRT, TSEBT, gem

flu/ melphalan,
alentuzumab

CR

2 mo

ND

Kikuchi,
2011122

1

Allogeneic,
DLI

6

F

Disseminated
skin lesions and
left inguinal
lymph node
metastasis

Positive: CD2, CD3, CD5
(very weak), CD8, CD45RO
(very weak), TIA, granzyme B
Negative: CD4, CD7, CD20,
CD30, CD45RA, CD56, TDT

etoposide,
melphalan, TBI

NR

0

ND

Moritz,
2014123

1

Allogeneic

27

M

ND

Fludarabine,
melphalan,
thiotepa, ATG

CR

14 mo

Wehkamp,
2015124

1

Allogeneic

48

M

TBI,
cyclophosphamide,
ATG

CR

36 mo

Cyclosporine A,
MTX/
mycophenolate
mofetil
Cyclosporine

Robson,
2015125

1

BMT

31

M

Generalized skin
involvement and
extensive lymph
node infiltration
Extensive
ulcerative
plaques and
patches
Ulcerated
patches, plaques,
nodules

CHOP, nelarabine
containing
combination
chemotherapy with
cyclophosphamide,
vincristine, Ara-C, Lasparaginase and
6-mercaptopurine
PUVA, LD-MTX,
acitretin, CHOEP,
pentostatin,
alemtuzumab, XRT
CHOP

ND

ND

ND

ND

Positive: CD8, TCR-β
Negative: ND

CHOP

Positive: CD7, CD8, CD45RA, PUVA,
MIB-1, β-F1
chemotherapy
Negative: CD2, CD3, CD4,
CD45RO

Treated with
lenalidomide following
relapse without
remission. Patient
succumbed to infection
Lesion remained
followed transplant,
treated with TSEBT,
DLI, before succumbing
to disease

Complicated by
bacterial colitis, EBV
activation, sepsis
GVHD

Dead

52

Paton,
126
2016

1

Autologous

57

M

Guitart,
112
2017

6

Allogeneic

19

F

Allogeneic

28

M

Psoriasiform
dermatitis

Allogeneic

46

F

Ulcerated nodule Positive: CD3, CD5, CD8,
TIA-1, β-F1
Negative: CD2, CD4, CD7,
CD30, CD56

Allogeneic

31

M

Necrotic
ulcerations

Allogeneic

63

M

Allogeneic

21

F

Plachouri,
2017127

1

Autologous,
allogeneic

47

M

Saruta,
2017128

1

Autologous

38

M

Ulcerated
plauqes and
tumors
Plaque, platch

Positive: CD3, CD8, CD7,
CD56, β-F1
Negative: CD4, CD30
Positive: CD3, CD5, CD7,
CD8, CD45RA, TIA-1,
Granzyme B, β-F1
Negative: CD2, CD4, CD30,
CD56
Positive: CD3 (partial), CD7,
CD8, CD30+ in Large Cells,
TIA-1, Granzyme B, β-F1
Negative: CD2, CD4, CD5,
CD56

Positive: CD3, CD7+ CD8,
CD45RA, TIA-1, β-F1
Negative: CD4, CD5, CD30,
CD56, Granzyme B
Patches, tumor
Positive: CD3, CD7, CD45RA,
TIA-1 subset, Granzyme B, βF1
Negative: CD4, CD5, CD8,
CD56
Ulcerated plaque Positive: CD2, CD3, CD7,
CD8 (weak), CD45RA, CD56,
TIA-1, Granzyme B, β-F1
(weak)
Negative: CD4, CD5, CD30
Disseminated
Positive: CD3, CD8, TIA-1,
ulcerative
granzyme B
plaques
Negative: CD4, CD30,
CD45RO, CD45RA, CD56
Multiple ulcerated Positive: CD3, CD8, TIA-1
erythematous
Negative: CD4, CD20, CD30
lesions

Systemic
chemotherapy

ND

ND

ND

ND

Dead

NM, TSEBT, romi,
EPOCH, Gem,
UCTH1,
bendamustine,

ND

5/6
CR

46 mo

ND

AWOD

TSEBT, BXT, romi,
Liposomal
doxorubicin,
vorinostat, PTX,
brentuximab,
CHOP, EPOCH,
gem, denileukin
diftitox
Phototherapy,
TSEBT, liposomal
doxorubicin, PTX,
brentuximab, gem,
bendamustine
Hyper-CVAD, BXT,
PUVA,

ND

168 mo

ND

AWD

ND

24 mo

ND

AWD

ND

84 mo

ND

AWD

CHOEP, TSEBT,

ND

10 mo

ND

Dead

EPOCH,
bendamustine,
DHAP, SMILE,
Gem, PTX, romi,
XRT
MTX, CHOEP,
DHAP

ND

16 mo

ND

AWOD

Etoposide,
interferon gamma,
CHOP

BEAM,
alemtuzumab

CR

60mo

ND

Complicated by therapy
related pancytopenia,
nausea, mucositis

CHASE, MCEC

CR

46 mo

N/A

Developed treatment
related AML, treated
with umbilical cord
blood transplant,
followed by relapse,
allogeneic SCT, patient
succumbed to sepsis
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Table 6: Treatment Alogrithm for CD8+ PCAETCL
Initial therapy for disseminated disease
CHOP, EPOCH, or other aggressive lymphoma regimen
If no complete remission achieved, second line regimens
Gemcitabine regimens
Pralatrexate
Brentuximab vedotin (if CD30+)
Nelarabine, alemtuzumab, bendamustine
Total skin electron beam radiotherapy
If complete remission achieved
Allogeneic stem cell transplant if patient is a candidate and has a donor
(consider total skin electron beam radiotherapy prior to transplant)
Minimal evidence to support role of autologous transplantation

Figures

CD3+

CD4 -

CD8+

CD2 -

CD5 -

CD7 -

TIA1+

CD56-

EBER -

Figure 1: Cytotoxic T cells are CD8+ with expression of cytotoxic markers such
as TIA-1
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Figure 2: CD8+ PCAETL atypical lymphocytes involving hair follicle
A

B

C

Figure 3: Variable presentations of CD8+ PCAETL (A) focal ulcer (Patient #2), (B)
patch/plaque (Patient #1), and (C) erosive, extensive (Patient #7)
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Discussion
A rapidly progressing form of cytotoxic CD8 positive T-Cell Lymphoma
was first described in 1990 by Agnarsson et al118, and named formally by Berti et
al119 in 1999. In the 1999 case series, 17 patients with CD8+ cutaneous
lymphomas were described, including a subset of patients with epidermotropic,
rapidly progressing, treatment resistant, and ultimately fatal disease. Since then,
there have been over 100 cases described in the literature including the largest
case series to date published in 2017112,129. Difficulty in distinguishing CD8+
PCAETL from its more indolent imitators can lead to delayed diagnosis and poor
outcomes, including published reports of patients dying prior to initiation of
treatment112,116. Additionally, the progressive nature and extreme severity of the
disease has led to a paucity of data regarding effective treatments. There is little
data documenting the response to novel agents such as HDAC inhibitors and
targeted antibody toxins.
In the largest case study to date, Guitart et al. observed that allogeneic
stem cell transplantation was the sole therapy that resulted in sustained
response of any type112. In order to define the role of transplantation in the
treatment of CD8+ PCAETL we identified 18 published cases of stem cell
transplantation. A summary of the findings can be found in Table 5. Of these, 3
occurred prior to the 2005 WHO classification. Of these 18 cases, 6 were
autologous bone marrow or peripheral blood stem cell transplants, 11 were
allogeneic stem cell transplants, and 2 were bone marrow transplants of
undocumented origin. There was one published report of two transplantations in

56
the same patient, an autologous transplantation followed by an allogeneic
transplant. The number of prior therapies ranged from 1-11, with a median of 3
prior therapies. Systemic chemotherapy was utilized in 16/18 cases, including all
cases after 1990. Complete or partial response was achieved in 13 patients, 3
had no response, while 2 patients lacked documentation of response. Of the 13
responding patients, only 2 had a reported relapse, though follow up information
was not reported or incomplete in some studies112,118,125,126. Autologous
transplantation resulted in durable response in 2/6 cases, while allogeneic
transplantation resulted in durable response in 9/11 cases. One case was
complicated by treatment related acute myelogenous leukemia which was
treated with an umbilical cord blood transplant and a second allogeneic
peripheral blood HSCT. The overall survival among patients receiving any type of
transplant was 55.6% at a median follow up of 24 months.
In our series of 8 patients with CD8+ PCAETL, 4 underwent allogeneic
stem cell transplantation, including one case of umbilical cord blood transplant.
One patient received infusion of donor lymphocytes for post transplant relapse,
and achieved remission with Brentuximab. All patients who received a transplant
were alive at the last follow up. No patients achieved durable remission with any
single or multi-agent systemic chemotherapy. Single agent HDAC inhibitor
therapy did not result in responses. A notable finding was the relative activity of
the novel agents pralatrexate and brentuximab vedotin in relapsed and refractory
patients. Brentuximab vedotin, an antibody-drug-conjugate directed against the
CD30 antigen, caused a partial or complete response in all three of the CD30
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positive patients and resulted in stable disease in a CD30 negative patient by
conventional immunohistochemistry.
Our limited series and review of the literature outline clinical challenges in
the treatment of CD8+ PCAETL with conventional chemotherapeutic approaches.
Unfortunately, many patients demonstrate resistance to multiple chemotherapy
agents and regimens; however, the advent of new therapy modalities and the
increased use of hematopoietic stem cell transplant has led to improved
outcomes and survival. Table 6 outlines a treatment algorithm for PCAETCL
based on available limited evidence. Our findings support implementation of an
aggressive strategy early in the course of treatment, including the consideration
of allogeneic stem cell transplant and donor search at the time of diagnosis.
Further, the use of novel agents earlier in the course of therapy remains to be
defined. Future studies should include molecular and genetic profiling of the
tumor in an effort to identify mutations and altered pathways that may lead to a
precision medicine approach for these patients.
Clinical Practice Points:


CD8+ PCAETL is a rare, rapidly progressive, and deadly disease, for
which no formalized treatment strategy exists, though HSCT have been
suggested a potential curative therapy



In this case series , four of eight patients underwent an allogeneic stem
cell transplant, resulting in a complete and durable remission in two
patients. All patients who received a transplant were alive at their last
follow up (median 45.5 months).



Brentuximab and pralatrexate demonstrated significant anti-disease
activity in relapse and resistant cases of CD8+ PCAETL, with overall
response rates of 100% and 60% respectively.
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Our study suggests that more aggressive use of HSCT, including early
consideration and donor search at time of diagnosis, may result in better
outcomes.



Further research is necessary to better understand the activity of novel
agents such as brentuximab and pralatrexate early in disease course.
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